Know Cancer

forgot password

A Phase 2 Study of AZD2171 (Cediranib) With Modified FOLFOX6 in Patients With Advanced Biliary Cancers

Phase 2
18 Years
Not Enrolling
Adult Primary Cholangiocellular Carcinoma, Advanced Adult Primary Liver Cancer, Cholangiocarcinoma of the Extrahepatic Bile Duct, Cholangiocarcinoma of the Gallbladder, Localized Unresectable Adult Primary Liver Cancer, Periampullary Adenocarcinoma, Recurrent Adult Primary Liver Cancer, Recurrent Extrahepatic Bile Duct Cancer, Recurrent Gallbladder Cancer, Unresectable Extrahepatic Bile Duct Cancer, Unresectable Gallbladder Cancer

Thank you

Trial Information

A Phase 2 Study of AZD2171 (Cediranib) With Modified FOLFOX6 in Patients With Advanced Biliary Cancers


I. To determine the response rate to AZD2171 (cediranib maleate) and modified folinic
acid-fluorouracil-oxaliplatin-6 regimen (FOLFOX 6) in subjects with advanced biliary


I. To determine overall assessment of toxicity of AZD2171 and modified FOLFOX6. II. To
determine the progression-free survival of subjects with advanced biliary cancers treated
with AZD2171 and modified FOLFOX6.

III. To determine overall survival of subjects with advanced biliary cancers treated with
AZD2171 and modified FOLFOX6.


Patients receive cediranib maleate orally (PO) once daily (QD) on days 1-14 and modified
FOLFOX6 comprising oxaliplatin intravenously (IV) over 2 hours, leucovorin calcium IV over 2
hours, and fluorouracil IV over 46 hours on day 1. Courses repeat every 14 days in the
absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed up every 3 months for 1 year,
every 6 months for 2 years, and then annually thereafter.

Inclusion Criteria:

- Patients with histopathological or cytopathological diagnosis of advanced biliary
carcinoma (gallbladder cancer, cholangiocarcinoma, ampullary cancer) not amenable to
conventional surgical approach are eligible

- Patients must have measurable disease, defined as at least one lesion that can be
accurately measured in at least one dimension (longest diameter to be recorded) as >
20 mm with conventional techniques or as > 10 mm with spiral CT scan

- No patients with untreated brain metastases

- Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2 (Karnofsky ≥ 60%)

- Life expectancy of greater than 12 weeks

- White blood cell (WBC)/leukocytes ≥ 3,000/μL

- Absolute neutrophil count ≥ 1,500/μL

- Platelets ≥ 100,000/μL

- Hemoglobin ≥ 9 g/dL

- Total bilirubin ≤ 3 mg/dL

- Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase
[SGOT])/alanine aminotransferase (ALT) (serum glutamic pyruvate transaminase [SGPT])
≤ 2.5 times institutional upper limit of normal

- Creatinine within normal institutional limits OR calculated creatinine clearance ≥ 60

- No patients with proteinuria not meeting the criteria below; urine sample must be
tested by urine protein:creatinine (UPC) ratio or by urinalysis method within 1 week
of starting study treatment; depending upon the testing method used, the following
criteria must be met:

- UPC ratio must be < 1.0; if UPC ratio is ≥ 1.0, a 24-hour urine specimen must be
collected and must demonstrate < 1 g of protein

- Urinalysis must indicate 0-1+ protein; if urinalysis reading is ≥ 2+, a 24-hour
urine specimen must be collected and must demonstrate < 1 g of protein

- Not pregnant or nursing

- Negative pregnancy test

- Fertile patients must use adequate contraception (hormonal or barrier method of birth
control; abstinence) before and during study treatment

- Acceptable contraception includes abstinence, oral contraceptives, intra-uterine
device (IUD), diaphragm, Norplant, approved hormone injections, condoms, or
documentation of medical sterilization

- Patients with evidence of heart disease must be New York Heart Association (NYHA)
Class I or II

- NYHA Class II patients controlled with treatment are considered at increased
risk for compromised left ventricular ejection fraction (LVEF) and will undergo
increased cardiac monitoring

- No patients with other active invasive cancers except nonmelanoma skin cancer or
carcinoma in-situ of the cervix

- History of prior cancer is allowed as long as there has been no evidence of
disease within the past 5 years

- No patients with mean corrected QT interval (QTc) > 480 msec (with Bazett's
correction) in screening electrocardiogram or history of familial long QT syndrome

- No patients with uncontrolled hypertension defined as systolic blood pressure (BP) ≥
140 mm Hg or diastolic BP ≥ 90 mm Hg, with or without anti-hypertensive medication or
history of hypertensive crisis or hypertensive encephalopathy

- Patients with initial BP elevations are eligible once their BP is controlled to
above parameters

- No patients with uncontrolled intercurrent illness including, but not limited to:

- Hypertension (> 140/90 mm Hg)

- Chronic or active infection requiring chronic suppressive antibiotics

- History of or symptomatic congestive heart failure requiring chronic medical

- NYHA class III or IV heart disease

- Unstable angina pectoris within 180 days prior to starting study treatment

- Myocardial infarction within 180 days prior to study treatment

- Gastroduodenal ulcer(s) determined by endoscopy to be active within 180 days
prior to study treatment

- Serious or non-healing wound, skin ulcers, or bone fracture

- Any significant bleeding that is not related to the primary tumor within 180
days prior to study treatment

- Known bleeding diathesis or coagulopathy

- Paresthesias, peripheral sensory neuropathy > gr. 1 per Common Terminology
Criteria for Adverse Events (CTCAE) v.4, or peripheral motor neuropathy ≥ gr. 2
per CTCAE v.4

- Psychiatric illness/social situations that would limit compliance with study

- No patients with history of transient ischemic attack (TIA) or cerebrovascular
accident (CVA) within 180 days prior to study treatment, symptomatic peripheral
ischemia; history of arterial thrombotic event within 180 days prior to study
treatment; gastrointestinal (GI) perforation within 180 days prior to study treatment

- Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral
therapy are ineligible

- Patients who are chemotherapy naive unless chemotherapy was given as adjuvant
post-surgical treatment and at least 6 months have elapsed since adjuvant

- No patients who have had major surgical procedures, open biopsies, or significant
traumatic injury within 28 days prior to study treatment

- Chemotherapy for prior cancer is permitted

- Eligibility of patients receiving any medications or substances known to affect or
with the potential to affect the activity or PK of AZD2171 will be determined
following review of their case by the Principal Investigator

- Efforts should be made to switch patients with brain metastases who are taking
enzyme-inducing anticonvulsant agents to other medications

- Patients may not be receiving any other investigational agents nor have participated
in an investigational trial within the past 30 days

- Patients may not be receiving any medication that may markedly affect renal function
(e.g., vancomycin, amphotericin, pentamidine)

- Patients may not be receiving therapeutic doses of Coumadin or equivalent

- No patients requiring drugs with proarrhythmic potential

Type of Study:


Study Design:

Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Estimation of the response rate of patients with advanced biliary cancers treated with cediranib maleate and modified FOLFOX6 evaluated using the Response Evaluation Criteria in Solid Tumors (RECIST) v1.1

Outcome Description:

Estimated based on the number of responses using a binomial distribution and its confidence intervals will be estimated using Wilson's method. The 95% confidence intervals should be provided.

Outcome Time Frame:

Up to 3 years

Safety Issue:


Principal Investigator

Smitha Krishnamurthi

Investigator Role:

Principal Investigator

Investigator Affiliation:

Case Western Reserve University


United States: Food and Drug Administration

Study ID:




Start Date:

October 2010

Completion Date:

Related Keywords:

  • Adult Primary Cholangiocellular Carcinoma
  • Advanced Adult Primary Liver Cancer
  • Cholangiocarcinoma of the Extrahepatic Bile Duct
  • Cholangiocarcinoma of the Gallbladder
  • Localized Unresectable Adult Primary Liver Cancer
  • Periampullary Adenocarcinoma
  • Recurrent Adult Primary Liver Cancer
  • Recurrent Extrahepatic Bile Duct Cancer
  • Recurrent Gallbladder Cancer
  • Unresectable Extrahepatic Bile Duct Cancer
  • Unresectable Gallbladder Cancer
  • Adenocarcinoma
  • Adenocarcinoma, Mucinous
  • Carcinoma
  • Liver Neoplasms
  • Gallbladder Neoplasms
  • Bile Duct Neoplasms
  • Cholangiocarcinoma



Fox Chase Cancer Center Philadelphia, Pennsylvania  19111
Arthur G. James Cancer Hospital and Solove Research Institute at Ohio State University Medical Center Columbus, Ohio  43210-1240
Case Medical Center, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center Cleveland, Ohio  44106-5065
Firelands Regional Medical Center Sandusky, Ohio  44870
Case Western Reserve University Cleveland, Ohio  44106
M D Anderson Cancer Center Houston, Texas  77030
Lombardi Comprehensive Cancer Center at Georgetown University Washington, District of Columbia  20057
Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center Cleveland, Ohio  44195
Lake University Ireland Cancer Center Mentor, Ohio  44060
Southwest General Health Center Ireland Cancer Center Middleburg Heights, Ohio  44130
UHHS-Chagrin Highlands Medical Center Orange Village, Ohio  44122
Ireland Cancer Center at Firelands Regional Medical Center Sandusky, Ohio  44870
Ireland Cancer Center Landerbrook Health Center Mayfield Heights, Ohio  44124
UH-Seidman Cancer Center at Saint John Medical Center Westlake, Ohio  44145